- Lobbying
- Lobbying by Novartis Services, Inc.
Lobbying Relationship
Bills mentioned
S.2041: Promoting Life-Saving New Therapies for Neonates Act of 2015
Sponsor: Bob Casey (D-Pa.)
H.R.3618: Orphan Drug Fairness Act
Sponsor: Leonard Lance (R-N.J.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Karissa Willhite | Menendez:DepCOS,DepExecDirHouseDemCauc,LA;Stenholm:LA |
Moses Mercado | Dep Chief of Staff, Gephardt; Chief of Staff, Green |
Bud Albright | UnderSecretary,DeptofEnergy;RepubStaffDir,HouseEnergy&Comm; Sr.OversightCouns,HouseCommerceComm;ChiefCouns,HouseCommDC |
Timothy McGivern | Chief of Staff, Senator Brownback |
Tony Bullock | Chief of Staff, Senator Daniel Moynihan |
Conrad Lass | SpcAsst/COS, BLM;LA,Thomas;Asst,Simpson |
Dean Aguillen | Advr, Pelosi; Dir Intgvt Aff, Labor; LA, Sandlin |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate